Table 2 Therapy characteristics.
Parameters | eRFA + CT (n = 40) | CT (n = 26) | P-value |
|---|---|---|---|
Lines of chemotherapy | 0.627 | ||
Only first-line | 31 (77.5) | 22 (84.6) | |
second-line or third-line | 9 (22.5) | 4 (15.4) | |
First-line protocol | 0.920 | ||
Gemcitabine/cisplatin | 29 (72.5) | 20 (76.9) | |
Gemcitabine/oxaliplatin | 2 (5.0) | 1 (3.8) | |
Gemcitabine mono | 9 (22.5) | 5 (19.2) | |
Second-line protocol | 0.165 | ||
FOLFIRI | 4 (50.0) | 1 (33.3) | |
Cetuximab/pembrolizumab | 3 (37.5) | 0 (0) | |
Capecitabine | 1 (12.5) | 2 (66.7) | |
N of first-line chemotherapy cycles | 5.5 (3.0; 10.3) | 6 (2; 8.3) | 0.680 |
N of eRFA | 2 (1; 4) | – | – |
eRFA procedure | – | ||
Endoscopic approach | 38 (95.0) | – | |
Percutaneous approach | 2 (5.0) | – | |
Emergency ERC | 11 (27.5) | 8 (30.8) | 0.774 |
PTCD | 0.249 | ||
Primary | 2 (5.0) | 2 (7.7) | |
After resection with alternated anatomy | 1 (2.5) | 8 (30.8) | |
Disease progression | 1 (2.5) | 1 (3.8) | |
SIRT | 1 (2.5) | 1 (3.8) | 0.755 |
Photodynamic therapy | 12 (30.0) | 8 (30.8) | 0.947 |
Prior surgical therapy | 0.254 | ||
No surgery | 19 (47.5) | 10 (38.5) | |
Curative intended resection with recurrence | 5 (12.5) | 7 (26.9) | |
Exploration, but no curative surgery possible | 13 (32.5) | 9 (34.6) | |
Metastatic surgery | 3 (7.5) | 0 (0) | |
